Nanotrap® Virus Particles capture and concentrate coronavirus OC43 for improved RT-PCR detection
APPLICATION NOTE SKU 44XXX
Key Advantages
> Nanotrap® processing is simple and efficient, creating quality input sample material for downstream detection.
> Bring low-abundance samples into the assay dynamic range and eliminate false negatives.
Introduction
Coronaviruses are a large family of viruses that usually cause mild to moderate upper-respiratory tract illnesses in humans. Three times in the 21st century, coronavirus outbreaks have emerged from animal reservoirs to cause severe disease and global transmission concerns, including the most recent outbreak for COVID-19 disease, caused by SARS-CoV-2.
Effective diagnostic tools are an essential element to the containment of any epidemic. A major challenge for public health authorities with the COVID-19 outbreak has been that it appears that asymptomatic patients are contagious for as long as 1-2 weeks. Additionally, the early nucleic acid tests that have been developed using reverse-transcription polymerase chain reaction (RT-PCR) are not sensitive enough to identify infections in many asymptomatic patients. According to the head of the Chinese Academy of Medical Sciences and an early study of samples collected in China in late 2019 and early 2020, 50% - 70% of infected patients were undetected due to false-negative test results.
Nanotrap® Virus Particles have already been shown to effectively capture and concentrate multiple strains of influenza and RSV, as well as the coronavirus strain 229E from saliva, thus enhancing detection, even in co-infection scenarios. Here we demonstrate the capture and concentration of a second coronavirus strain (HCoV-OC43) from viral transport media (VTM) for improved RT-PCR detection, suggesting that Nanotrap® Virus Particles might be able to capture and concentrate additional strains of coronavirus, including SARS-CoV-2.
Opmerkingen